CLINICAL STAGE III GASTRIC CANCER AJCC V8
Clinical trials for CLINICAL STAGE III GASTRIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III GASTRIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III GASTRIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (trastuzumab deruxtecan and azenosertib) in people with HER2-positive stomach, gastroesophageal junction, or other solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New combo shows promise for tough stomach cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for advanced cancers with DNA repair flaws: PARP inhibitor trial opens
Disease control Recruiting nowThis study tests the drug talazoparib in adults with advanced solid tumors (like breast, prostate, ovarian, pancreatic, or stomach cancer) that have certain gene changes affecting DNA repair. The drug blocks a protein called PARP, which cancer cells need to fix their DNA, potenti…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
New drug combo shows promise for tough stomach cancers
Disease control Recruiting nowThis early-phase study tests two drugs, pembrolizumab and lenvatinib, in about 15 people with advanced stomach or gastroesophageal cancer that has spread or can't be surgically removed. Pembrolizumab helps the immune system attack cancer cells, while lenvatinib blocks enzymes tha…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:23 UTC
-
New chemo cocktail aims to extend life in hard-to-treat stomach cancers
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunotherapy nivolumab…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
Ear acupressure: a new hope for cancer appetite loss?
Symptom relief Recruiting nowThis study tests whether a simple, non-invasive technique called auricular acupressure (using small pellets on the ear) can help improve appetite and prevent weight loss in people with advanced stomach, esophageal, or pancreatic cancer. About 66 participants will receive either a…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated May 17, 2026 04:16 UTC